The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. (Q38076349)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1 reference

title

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Alyssa Fischer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Shenhong Wu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alan L Ho

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

24 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

787-797

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23345001%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-013-9927-x

22 February 2020

exact match

0 references

cites work

Angiogenesis and angiogenic inhibitors in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Concise drug review: pazopanib and axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Antiangiogenic agents: an update on small molecule VEGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9927-X

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

21 January 2018

1 reference

12 December 2020

A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma

1 reference

12 December 2020

Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma

1 reference

12 December 2020

The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

1 reference

12 December 2020

Non-rash skin toxicities associated with novel targeted therapies

1 reference

12 December 2020

Dermatologic toxicities of targeted anticancer therapies.

1 reference

12 December 2020

Axitinib for renal cell carcinoma

1 reference

12 December 2020